Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coronavirus Update: Moderna Progesses To Phase II, Russia Approves Homegrown Antiviral

CanSino Has Produced Fuller Data

Executive Summary

Moderna maintains its lightning pace, but questions about its Phase III trial design remain.

You may also be interested in...



Celltrion Progresses COVID-19 Antibody Therapeutic, Pricing Will Be Key

Celltrion presses ahead with Phase I study of COVID-19 antibody therapeutic, encouraged by the support of the South Korean government. The firm also urges global cooperation to lower prices of COVID-19 drugs and vaccines to end the global pandemic.

Moderna’s COVID-19 Vaccine Spurs Immune Response In All Phase I Subjects At All Doses

Neutralizing antibodies were seen in all 45 people injected across three dose levels in the first-in-human study. The middle dose of 100mcg will be tested in the company’s Phase III trial starting 27 July.

Tripartite Avigan Alliance Aims For Global Access

Fujifilm Toyama seals three-way deal to accelerate the development and global supply of favipiravir, close on the heels of the arrival of a generic version of the antiviral in India under restricted emergency use for the treatment of COVID-19.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel